West China Hosptial, Sichuan University
Chengdu, Sichuan, 610041, China
NCT Number: NCT01345643
Guidelines for blood transfusion have been issued for years. According to these guidelines, red blood cells (RBCs) transfusion should be given when the hemoglobin level is less than 6g/dL or 7g/dL and is unnecessary when the level is more than 10g/dL. However, in all the guidelines, the determination of whether RBCs should be administered when the hemoglobin level is in the range of 7~10g/dL is based on the judgment from anesthesiologists or surgeons. Index of transfusion trigger for patients with hemoglobin level between 7/dL and 10g/dL is necessary and important in clinical practice. Based on the aim of blood transfusion that maintain the balance of oxygen supply and oxygen consumption, the investigators hypothesize that index of transfusion trigger for patients with hemoglobin level between 7/dL and 10g/dL could be calculated by their history about heart and blood pressure, and routine monitoring parameters including pulse oximetry, temperature, and the use of vasoactive medications. To verify this hypothesis, the investigators present West China Perioperative Transfusion Score (WCPTS) for the trigger of transfusion according to the patient's history and monitoring parameters, and the investigators design a randomized controlled clinical trial to test this score.
Looking for future studies?
Notify Me15 year–70 year
All sexes
Interventional
Not applicable
Chengdu, Sichuan, 610041, China
Surgery and trauma are the most common reasons for major blood loss, and blood transfusion provide guarantee for massive hemorrhagic surgery, especially orthopedic, cardiac, liver, and gynecologic procedures. On the other hand, blood transfusion is associated with many risks including hemolytic and nonhemolytic reactions, transfusion related acute lung injury, and others. Besides, blood is insufficient worldwide. How to eliminate allogeneic blood transfusion is an important part in clinical practice.
Guidelines for blood transfusion have been issued by many health institutions or organizations in different countries. According to these guidelines, red blood cells (RBCs) transfusion should be given when the hemoglobin level is less than 6g/dL or 7g/dL and is unnecessary when the level is more than 10g/dL. However, in all the guidelines, the determination of whether RBCs should be administered when the hemoglobin level is in the range of 7~10g/dL is based on the judgment from anesthesiologists or surgeons on the patient's condition including intravascular volume status, ongoing bleeding, any risk factors for vital organs ischemia or hypoxia, and so on. Index of transfusion trigger for patients with hemoglobin level between 7/dL and 10g/dL is necessary and important in clinical practice.
The aim of blood transfusion is to provide sufficient oxygen for the whole body, and to maintain the balance of oxygen supply and oxygen consumption. Factors associated with oxygen supply are hemoglobin level, cardiac output (CO), and oxygen saturation. Oxygen consumption is increased by the increase of metabolism, which could be reflected by increase of heart rate, blood pressure, and body temperature. If a patient's oxygen supply is decreased or oxygen consumption is increased, he will need a higher hemoglobin level to maintain the balance. Based on these findings, the investigators hypothesize that index of transfusion trigger for patients with hemoglobin level between 7/dL and 10g/dL could be calculated by their CO (reflected by the use of adrenalin), and routine monitoring parameters including pulse oximetry and core temperature.
West China Perioperative Transfusion Score (WCPTS)
The initial score is 7.
If a patient's cardiac output (CO) is normal without continuous infusion of adrenalin, or his SpO2 is more than 95%, or his core temperature is less than 38℃, he doesn't have any bonus point factor, and his score is 7.
If a patient's CO is maintained in normal range by continuous adrenalin infusion with concentration of less than 0.05μg/kg.min, or his SpO2 is 85~94%, or his core temperature is 38~40℃, his score should be added 1 point for every item mentioned above.
If a patient's CO is only maintained by continuous adrenalin infusion with concentration of more than 0.05μg/kg.min, or his SpO2 is less than 84%, or his core temperature is above 40℃, his score should be added 2 points for every item mentioned above.
For example, if a patient's CO is normal, his SpO2 is more than 95%, and his core temperature is 39℃,his WCPTS should be calcultaed as 7 plus 1 (core temperature is 39℃), and his final score is 8.
Here's another example, if a patient's CO is normal, his core temperature is less than 38℃, but he has COPD and his SpO2 is less than 84%, his score could be calculated as 7 plus 2(SpO2 is less than 84%), and his final score is 9.
Value of SaO2 is evaluated 5min after endotracheal intubation with inhalation of compressive air.
The initial score is 7,and the patient's score is calculated by 7 plus the sum of every item.
Score 7:To maintain the patient's Hb level not less than 7g/dL
Score 8:To maintain the patient's Hb level not less than 8g/dL
Score 9:To maintain the patient's Hb level not less than 9g/dL
Score 10 or >10:To maintain the patient's Hb level not less than 10g/dL
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
Time frame: Up to 12 weeks.
Proportion of patients who received red blood cells transfusion (Patients received red cells transfusion/ total number of the patients)
Time frame: Up to 12 weeks.
Volume of red blood cells transfused to the patients (units)
Time frame: Up to 30 days post-operatively.
Death for any reason within 30 days post-operatively
Time frame: Up to 12 weeks.
In-hospital complications include: (1) Cardiac and pulmonary events such as cardiac arrest, arrhythmia, heart failure, pulmonary edema, etc. (2) Febrility without antibiotic treatment. (3) Infection needed antibiotic treatment. (4) Re-operation for bleeding. (5) Deep venous thrombosis. (6) Other complications.
Time frame: Up to 12 weeks.
Hb level at admission, 1 day before surgery, during operation, 1,2,3 days after surgery, before discharge
Time frame: Up to 12 weeks.
From admission to ICU to discharge from ICU
Time frame: Up to 12 weeks.
All the medical costs.
Time frame: Up to six months postoperatively
The time period (days) from the day of operation to the day of stitches removal
Time frame: Up to six months postoperatively
Healing status is divided into grade Ⅰ, Ⅱ, and Ⅲ. Grade Ⅰ was defined as the wound healing nicely without any adverse reaction, grade Ⅱ was defined as the inflammatory wound without the need of re-incision, and grade Ⅲ was defined as the wound suppurated with the need of re-incision for clearance.
Time frame: Up to six months postoperatively
Tthe time period (weeks) from the day of discharge to the day that patient get recovery of normal daily life and/or working during a six-month follow-up.
Ren Liao
Other
A Randomized Controlled Clinical Trial of Transfusion Under the Guidance of West-China Perioperative Transfusion Score(WCPTS)for Massive Hemorrhagic Surgery
Acronym: WCPTS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01597232
Transfusion Related Complications
Chengdu, Sichuan, China
View Trial DetailsNCT01714297
Arthritis of the Hip, Hemorrhage
Sandvika, Gjettum, Norway
View Trial DetailsNCT01369719
Anemia, Anemia, Hemolytic
Bandar Abbas, Hormozgan, Iran
View Trial DetailsNCT06632314
Feeding Intolerance, Necrotizing Enterocolitis of Newborn
Antalya, Konyaalti, Turkey (Türkiye)
View Trial Details